Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXTW), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT, LIXTW) is a clinical-stage pharmaceutical company focused on oncology, with news flow centered on its lead PP2A inhibitor LB-100 and related corporate initiatives. Company press releases highlight ongoing proof-of-concept clinical trials of LB-100 in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma, often in collaboration with leading cancer centers such as The University of Texas MD Anderson Cancer Center, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Netherlands Cancer Institute.
Investors following LIXTE news can track updates on clinical trial enrollment, trial expansions, and scientific validation of the LB-100 mechanism, including references to findings published in journals such as Nature. The company also issues news on strategic collaborations with pharmaceutical manufacturers, support from partners like GSK and F. Hoffmann-La Roche, and developments in its broader oncology platform.
LIXTE’s news stream includes financing and capital markets activities, such as private placements, registered direct offerings and shelf registrations on Form S-3 and Form S-1, as well as updates on Nasdaq listing compliance. Corporate governance items, including Board and management changes, formation of scientific advisory structures, and relocation of corporate headquarters, are also covered in its announcements.
Another theme in LIXTE’s disclosures is its treasury and strategic expansion policy, including Board-approved allocation of a portion of its treasury to cryptocurrencies and subsequent purchases of Bitcoin and Ethereum, along with the acquisition of Liora Technologies Europe Ltd. and its LiGHT proton therapy system. For readers interested in oncology pipelines, capital strategy and emerging radiotherapy technologies, this news page aggregates LIXTE’s latest press releases and regulatory communications in one place.
LIXTE Biotechnology Holdings announced new pre-clinical data published in EMBO Reports showing that its lead compound, LB-100, can potentially enhance immunotherapy effectiveness in colon cancer. LB-100 has been found to disrupt mRNA splicing in cancer cells, creating neo-antigens that boost immune system recognition. This mechanism could help turn immunologically 'cold' tumors 'hot,' making them more susceptible to immunotherapy. The study, conducted by researchers at the Netherlands Cancer Institute, adds to existing data supporting LB-100's role in sensitizing cancer cells to immune checkpoint blockade. This discovery is expected to expand clinical trial efforts, particularly in lung and ovarian cancer, and could significantly increase the number of colon cancer patients responding to immunotherapy.
LIXTE Biotechnology Holdings has appointed Dr. Jan Schellens as the new Chief Medical Officer, effective August 1, 2024, succeeding Dr. James S. Miser.
Dr. Schellens brings over 25 years of clinical experience in oncology and pharmacology, including leadership roles at prominent institutions like the Netherlands Cancer Institute.
He is expected to significantly contribute to LIXTE's development of LB-100, which aims to enhance chemotherapy and immunotherapy treatments. Dr. Schellens has co-authored over 900 scientific publications and has had significant roles on various medical boards and advisory committees.
LIXTE CEO Bas van der Baan expressed confidence in Dr. Schellens' ability to drive the company's growth and development in cancer therapeutics.
LIXTE Biotechnology provided an update on their recent activities. Key highlights include promising pre-clinical data on their compound LB-100 in a new field of cancer biology called 'activation lethality.' The findings suggest that LB-100 can force cancer cells to lose their cancer-causing properties, potentially opening new treatment strategies alongside ongoing clinical trials in lung, ovarian, and sarcoma cancers. The data was presented by Dr. René Bernards at a major cancer research conference and published in the journal Cancer Discovery.
CEO Bas van der Baan presented at the MedInvest Biotech and Pharma Investor Conference. LIXTE co-sponsored an international workshop at Harvard’s Dana Farber Cancer Institute, discussing innovative cancer therapy approaches. Clinical trials for LB-100 are underway at various prestigious institutions, including the University of Texas MD Anderson Cancer, City of Hope Cancer Center, Sarah Cannon Research Institute, and the Spanish Sarcoma Group. In February 2024, LIXTE signed an exclusive patent license agreement with the NIH. The company's latest financial data is available in their quarterly report filed with the SEC.
LIXTE Biotechnology Holdings, a clinical stage pharmaceutical company, is co-sponsoring an international scientific conference on "Therapeutic Over-Activation in Cancer" at Harvard University's Dana Farber Cancer Institute. The conference will discuss LIXTE's lead clinical compound, LB-100, which has shown promising results in triggering hyper-activation of signals leading to the death of cancer cells. LIXTE's unconventional approach to cancer therapy is based on over-activating oncogenic signaling, presenting a new treatment strategy in cancer therapy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.